{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:08:09Z","timestamp":1788905289297,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.07.032","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:05:34Z","timestamp":1785427534000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cis-targeted IL-2 Mutein to Augment the Antitumor Activity of Engineered T Cells"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1922-4663","authenticated-orcid":false,"given":"Sara","family":"Sleiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-2609","authenticated-orcid":false,"given":"Nathan D.","family":"Mathewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kimberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Shestova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Shestov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslaw","family":"Kozlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Jarocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Duran-Struuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rossari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-5614","authenticated-orcid":false,"given":"Asuncion Borrero","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2958-093X","authenticated-orcid":false,"given":"Shujing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-7690","authenticated-orcid":false,"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Sukthankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-3588","authenticated-orcid":false,"given":"Danielle C.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindy","family":"Liao-Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D.","family":"Moynihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yik Andy","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Djuretic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saar","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.07.032_bib0001","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0002","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0003","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","article-title":"Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia","volume":"6","author":"Grover","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.07.032_bib0004","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0006","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0008","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0009","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.07.032_bib0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2026.07.032_bib0011","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.ymthe.2023.07.015","article-title":"Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling","volume":"31","author":"Tennant","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.07.032_bib0012","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0014","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.07.032_bib0016","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering IL-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0018","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/cells12091316","article-title":"Rethinking oncologic treatment strategies with interleukin-2","volume":"12","author":"Ko","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jtct.2026.07.032_bib0019","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2\u2013based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtct.2026.07.032_bib0021","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtct.2026.07.032_bib0022","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imm.13460","article-title":"Distinguishing activated T regulatory cell and T conventional cells by single-cell technologies","volume":"166","author":"Reinhardt","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.jtct.2026.07.032_bib0023","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41467-019-12901-3","article-title":"Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist","volume":"11","author":"Parisi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.07.032_bib0024","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.07.032_bib0025","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/2159-8290.CD-20-0786","article-title":"Pegylated engineered IL2 plus anti\u2013PD-1 monoclonal antibody: the nectar comes from the combination","volume":"10","author":"Rouanne","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2026.07.032_bib0026","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u201csuperkine","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2026.07.032_bib0027","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117401119","article-title":"Interleukin-2 superkines by computational design","volume":"119","author":"Ren","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtct.2026.07.032_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","volume":"10","author":"Merchant","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.07.032_bib0029","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","article-title":"IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity","volume":"14","author":"Moynihan","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2026.07.032_bib0030","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1038\/s41467-019-11782-w","article-title":"A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control","volume":"10","author":"Sun","year":"2019","journal-title":"Nat Commun"},{"issue":"Suppl. 15","key":"10.1016\/j.jtct.2026.07.032_bib0031","doi-asserted-by":"crossref","first-page":"abstr.5510","DOI":"10.1200\/JCO.2021.39.15_suppl.5510","article-title":"Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-\u03b1, combined with atezolizumab in patients with recurrent or metastatic cervical cancer","volume":"39","author":"Italiano","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0032","doi-asserted-by":"crossref","first-page":"LB041","DOI":"10.1158\/1538-7445.AM2021-LB041","article-title":"THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced\/metastatic solid tumors: interim results from HAMMER, an open-label, multicenter phase 1\/2 study","volume":"81","author":"Janku","year":"2021","journal-title":"Cancer Res"},{"issue":"Suppl. 15","key":"10.1016\/j.jtct.2026.07.032_bib0033","doi-asserted-by":"crossref","first-page":"abstr.2513","DOI":"10.1200\/JCO.2021.39.15_suppl.2513","article-title":"ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumors","volume":"39","author":"Boni","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0034","doi-asserted-by":"crossref","first-page":"eabg7565","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0035","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0036","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0037","doi-asserted-by":"crossref","first-page":"eadi1572","DOI":"10.1126\/scitranslmed.adi1572","article-title":"CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus","volume":"16","author":"Andreata","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0038","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/2159-8290.CD-23-1263","article-title":"CD8-targeted IL2 unleashes tumor-specific immunity in human cancer tissue by reviving the dysfunctional T-cell pool","volume":"14","author":"Kaptein","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2026.07.032_bib0039","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.07.032_bib0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtct.2026.07.032_bib0041","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2026.07.032_bib0042","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bpj.2018.08.018","article-title":"Computational model of chimeric antigen receptors explains site-specific phosphorylation kinetics","volume":"115","author":"Rohrs","year":"2018","journal-title":"Biophys J"},{"key":"10.1016\/j.jtct.2026.07.032_bib0043","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41586-020-2851-2","article-title":"Immune receptor inhibition through enforced phosphatase recruitment","volume":"586","author":"Fernandes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2026.07.032_bib0044","doi-asserted-by":"crossref","first-page":"104614","DOI":"10.1016\/j.ebiom.2023.104614","article-title":"Patient-derived melanoma organoid models facilitate the assessment of immunotherapies","volume":"92","author":"Ou","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtct.2026.07.032_bib0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0046","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0047","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","article-title":"In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2","volume":"134","author":"Lotze","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0048","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.032_bib0049","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2026.07.032_bib0050","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.07.032_bib0051","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/protein\/gzp085","article-title":"Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity","volume":"23","author":"Taylor","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.jtct.2026.07.032_bib0052","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtct.2026.07.032_bib0053","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","article-title":"Potentiating adoptive cell therapy using synthetic IL-9 receptors","volume":"607","author":"Kalbasi","year":"2022","journal-title":"Nature"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:20:31Z","timestamp":1788902431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"alternative-id":["S2666636726005944"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.032","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cis-targeted IL-2 Mutein to Augment the Antitumor Activity of Engineered T Cells","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}